linjc16/ctgov huggingface dataset:
Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion

Study Overview
=================
Brief Summary
-----------------
This research study is being conducted to help improve the pre-operative, intra-operative, and post-operative course for patients and enhance recovery.

Official Title
-----------------
Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion

Conditions
-----------------
Degenerative Spinal Arthritis, Cervical Myelopathy, Spinal Stenosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 89 Diagnosis of cervical myelopathy, cervical stenosis, cervical disc disorder, or cervical spondylolisthesis Exclusion Criteria: Cervical injury as the indication for surgery Emergent surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay | We will record the length of stay (date of admission to date of discharge) for the operative admission at the time of discharge. | Will record length of stay in days 3 months following admission date. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of readmission |  | Within 3 months of discharge | 
| Numerical rating scale (NRS)- pain | Numerical score of neck pain. Scored 0 to 10. 10 is the worst pain. | immediately before, immediately after, and 3 months after surgery | 
| SF-12 short form | SF-12 short form health survey. Scored 0 to 100. 100 is the highest level of health. | immediately before, immediately after, and 3 months after surgery | 
| Oswestry Disability Index | questionnaire regarding low back pain. Scored 0 to 100. 100 being most severe disability. | immediately before, immediately after, and 3 months after surgery | 
| Number of sessions with physical therapy and occupational therapy | record of number of sessions completed with physical or occupational therapy during the operative admission. We will determine this number at the time of discharge. We will calculate this number only once. | will record number of physical and occupational therapy sessions during surgical admission 3 months following admission date | 
| Disposition status | We will determine the disposition status at the time of discharge following the operative admission. We will do this only once. | will record discharge disposition 3 months following surgical admission date |
Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients

Study Overview
=================
Brief Summary
-----------------
An increased number of patients with heparin-induced skin lesions is reported in the literature. Heparin-induced skin lesions may result from either occlusion of cutaneous vessels in patients suffering from autoimmune HIT or from a type IV allergic reaction (delayed type hypersensitivity (DTH) response). However, the incidence and nature of heparin-induced skin lesions has not been determined in a prospective investigation. To address this open issue is the goal of this ongoing, so far monocenter, clinical investigation.

Official Title
-----------------
Inzidenz Und Art Heparin-induzierter Hautveränderungen

Conditions
-----------------
Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 Y. s.c. anticoagulant therapy >6 days Exclusion Criteria: history of HIT history of DTH to heparin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| s.c. anticoagulant therapy<br>All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
heparin, heparin-induced thrombocytopenia, HIT, allergy, skin, dermatology, DTH, delayed-type hypersensitivity, histology, Patients receiving sc heparin therapy, Age over 18 years, Recruitment will stop when 20 patients with skin lesions are included
Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Etodalac, Etoricoxib and Dexamethasone are effective for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery

Official Title
-----------------
Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery: A Prospective, Double-Blind Study

Conditions
-----------------
Trismus, Edema, Pain

Intervention / Treatment
-----------------
* Drug: Etodalac, Etoricoxib and Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are refered for third molar extraction to our center Must be able to swallow tablets Exclusion Criteria: Diabetes mellitus Thyroid diseases Cardiovascular diseases renal diseases hepatic diseases respiratory system diseases adrenal diseases Allergy to Etodalac, Etoricoxib or Dexamethasone Gastric ulcers psychiatric diseases Pregnant or breast feeding womans

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: Etodalac, Etoricoxib and Dexamethasone<br>* Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction. Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction. Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PAIN- By VAS graded from 1-10 TRISMUS- By MAX mouth opening from the first incisors adages POST OPERATIVE SWELLing - By measurement the distance between the Right and LEFT ear's tragus |  | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trismus, Edema, pain
Changes Following Inpatient Child-oriented Family Treatment

Study Overview
=================
Brief Summary
-----------------
Children receiving IFT (intensive family therapy) were assessed for symptom profile and global functioning before admission, 3 months after discharge and 1 year after discharge. Children were assessed by parents, children, their teachers and themselves. Parents were assessed by themselves at the same points in time through psychological self-report questionnaires. The study is intended to explore covariates to change in children as well as in parents during (pre-treatment) the treatment and follow-up periods.

Detailed Description
-----------------
IFT is an intensive combinatory family treatment which is child-oriented, and traditionally used in an inpatient family treatment unit in child and adolescent psychiatry. Measures include ones on bonding (PBI), personality traits (NEO-PI), anxiety and depressive symptoms (HADS), attributional tendencies (PAT) and social desirable responding (BIDR). A subgroup was also assessed before a waiting period (pre-treatment).

Official Title
-----------------
Change Across Intensive Inpatient Family Treatment in Child and Adolescent Psychiatry. A Multi-site Study of Parents and Children in Inpatient Family Treatment

Conditions
-----------------
Psychiatric Disorders

Intervention / Treatment
-----------------
* Behavioral: Intensive family therapy - inpatient
* Behavioral: Diagnostic assessment - child and adolescent psychiatry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Family offered inpatient family treatment in child and adolescent psychiatry. Exclusion criteria inpatient treatment terminated prematurely

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment|
|Behavioral: Diagnostic assessment - child and adolescent psychiatry|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Severe and longstanding psychiatric symptoms in children
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Study Overview
=================
Brief Summary
-----------------
This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: MK0767


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes with inadequate glycemic control Patient is on stable insulin therapy alone or with one oral antidiabetic agent Male or non-pregnant female 21 years or older Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day Exclusion Criteria: Have a history of type 1 diabetes mellitus History of ketoacidosis who are being treated with insulin Are taking 2 or more antidiabetic agents in combination with insulin

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0767|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Pesticide Exposure Pathways for Farmworker Children

Study Overview
=================
Brief Summary
-----------------
This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. The current project will characterize pesticide exposure pathways for children of farmworkers.

Detailed Description
-----------------
This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. Since 1991 our group has investigated pesticide expsoures among children of agricultural families in Washington state, focusing on exposure to organophosphate insecticides. We have demonstrated in these studies that the residential environments of agricultural families have higher pesticide residues than do other homes in this region. We have also found that children living in these residential environments have elevated levels of pesticide metabolites in their urine. We need to better understand how these children are being exposed in order to develop recomendations for exposure prevention or reduction. The current project will characterize pesticide exposure pathways for children of farmworkers. A complementary project is also underway by the UW-Child Health Center to develop and implement a community-wide intervention to reduce the transfer of pesticides from the workplace to the home (take home pathway).

Official Title
-----------------
Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers (UW IRB 96-6567-C02, FENSKE, 6/15/00-6/14/01)

Conditions
-----------------
Poisoning

Participation Criteria
=================
Eligibility Criteria
-----------------
Each family recruited must include one child between the ages of 1-5.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pesticide, insecticide, organophosphate, exposure, child health
The Association Between Preoperative CPEX and Postoperative Morbidity Following Oesophagectomy

Study Overview
=================
Brief Summary
-----------------
A retrospective hospital-based cohort study of the association between preoperative cardiopulmonary exercise test (CPEX) variables and short-term postoperative morbidity following oesophagectomy.

Detailed Description
-----------------
The aim of this study is to examine the correlations between preoperative CPEX variables (VO2max and Anaerobic Threshold) and 30 day postoperative all cause morbidity in a sample large enough to allow (should significant associations exist) calculation of a threshold value. Secondary aims are to examine associations between the VO2max, AT and cardiopulmonary, non-cardiopulmonary complications as well as specific complications (atrial fibrillation, pneumonia, and anastomotic leak) as well as 30 and 90 day mortality.

Official Title
-----------------
The Association Between Preoperative Cardiopulmonary Exercise Test Variables and Short-term Postoperative Morbidity Following Oesophagectomy: a Hospital-based Cohort Study

Conditions
-----------------
Oesophageal Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Cardiopulmonary exercise testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: i. male and female ii. underwent an oesophagectomy iii. completed a pre-operative CPEX test Exclusion Criteria: i. patients that were unable to complete a full CPEX test ii. emergency or palliative surgery iii. pharyngolaryngo-oesophagectomy iv. oesophagectomy and gastrectomy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause postoperative morbidity | Classified using Esophageal Complications Consensus Group (ECCG) definitions [1] and graded using Clavien-Dindo severity classification [2]. | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiopulmonary complications | Classified using ECCG definitions and graded using Clavien-Dindo severity classification. | 30 days | 
| Non-cardiopulmonary complications | Classified using ECCG definitions and graded using Clavien-Dindo severity classification. | 30 days | 
| Mortality | All cause mortality. | 30 days | 
| Mortality | All cause mortality. | 90 days | 
| Pneumonia | Classified using ECCG definitions and graded using Clavien-Dindo severity classification. | 30 days | 
| Atrial fibrillation | Classified using ECCG definitions and graded using Clavien-Dindo severity classification. | 30 days | 
| Anastomotic leak | Classified using ECCG definitions and graded using Clavien-Dindo severity classification. | 30 days |
Pain Relief During Repair of Postpartum Perineal Tears

Study Overview
=================
Brief Summary
-----------------
The aim of our study is to compare the analgesic effect of topical application of lidocaine-prilocaine cream and lidocaine infiltration during repair of postpartum perineal tears.

Official Title
-----------------
Topical Lidocaine-prilocaine Cream Versus Lidocaine Infiltration for Pain Relief During Repair of Postpartum Perineal Tears: A Randomized Controlled Trial

Conditions
-----------------
Improving Quality of Life

Intervention / Treatment
-----------------
* Drug: lidocaine injection
* Drug: lidocaine-prilocaine cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gestational age > 37 weeks Uncomplicated pregnancy Single vertex fetus Normal vaginal delivery Women who will accept to participate in the study Exclusion Criteria: Women received epidural analgesia Women required episiotomy Women with intact perineum Operative vaginal delivery Allergy to the used drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: lidocaine injection<br>5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection. | Drug: lidocaine injection<br>* anhydrous solution<br>* Other names: depocaine;|
| Experimental: lidocaine-prilocaine cream<br>5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing | Drug: lidocaine-prilocaine cream<br>* topical cream<br>* Other names: pridocaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean pain score during suture of perineal tears |  | 30 minutes |
Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Intradialytic blood pressure and dialysis efficacy (in terms of urea removal) improve under electrical muscle stimulation or passive leg movement on a treadmill.

Official Title
-----------------
Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy

Conditions
-----------------
Hypotension

Intervention / Treatment
-----------------
* Device: transcutaneous muscle stimulation, treadmill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dialysis patients able to put legs on a treadmill Exclusion Criteria: Dialysis duration shorter than 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: transcutaneous muscle stimulation, treadmill|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  |  | 
| Urea removal |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of hypotensive episodes on dialysis |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dialysis associated hypotension, Urea removal
A Clinical Investigation of the Taperloc® Microplasty™ Hip System

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective clinical data-collection is to document the performance and clinical outcomes of the Taperloc® Microplasty™ Hip System.

Official Title
-----------------
A Prospective, Non-controlled, Clinical Investigation of the Taperloc® Microplasty™ Hip System

Conditions
-----------------
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis Rheumatoid arthritis. Correction of functional deformity. Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques. Revision of previously failed femoral head resurfacing component Exclusion Criteria: Absolute contraindications include: infection, sepsis, and osteomyelitis. Relative contraindications include: uncooperative patient or patient with neurologic disorders who are incapable of following directions, osteoporosis, metabolic disorders which may impair bone formation, osteomalacia, distant foci of infections which may spread to the implant site, rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram, vascular insufficiency, muscular atrophy, or neuromuscular disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Taperloc® Microplasty™ Hip System<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Harris Hip Score |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of revision or removals |  | 5 Years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total Hip Replacement, Total Hip Arthroplasty, Minimally Invasive, Microplasty, Hip Arthritis